Related Experiment Videos
[Severe contact dermatitis caused by Parfenac cream]
E Collet1, M Lacroix, C Boulitrop Morvan
1Service de Dermatologie, Hôpital du Bocage, Dijon.
Annales De Dermatologie Et De Venereologie
|January 1, 1993
Summary
Bufexamac, a topical anti-inflammatory, can cause severe contact dermatitis. Patch-tests confirmed bufexamac and Parfenac cream triggered this adverse reaction in a patient.
Area of Science:
- Dermatology
- Pharmacovigilance
Background:
- Bufexamac is a topical anti-inflammatory medication prescribed for pruritic skin conditions.
- Post-marketing surveillance has linked bufexamac to adverse skin reactions, including contact dermatitis and toxicodermia.
Observation:
- A patient developed severe contact dermatitis following the topical application of bufexamac (Parfenac) cream.
- The clinical presentation included symptoms consistent with eczema and urticaria.
Findings:
- Patch testing, conducted two months post-resolution of the acute phase, revealed strong positive reactions (+ + +) to both Parfenac cream and pure bufexamac.
- These results definitively establish bufexamac as the causative agent for the patient's severe contact dermatitis.
Implications:
- This case highlights the potential for bufexamac to induce severe contact dermatitis, emphasizing the need for careful patient selection and monitoring.
- Healthcare providers should be aware of this risk and consider alternative treatments for patients with suspected bufexamac hypersensitivity.
- Further pharmacovigilance studies may be warranted to better define the incidence and risk factors associated with bufexamac-induced contact dermatitis.